Carlsmed, Inc.

Ladies and gentlemen, thank you for standing by and welcome to the CARLS-Med first quarter 2026 earnings conference call. At this time, all participants are in the listening only mode. After the speaker's presentation, there will be a question and answer session. I would now like to turn the conference over to your first speaker today, Stephanie Zadkovich.

Thank you, Operator.

Welcome to Carls Med's first quarter 2026 earnings call. Joining me on today's call are Mike Cordonier, Chairman and Chief Executive Officer, and Leo Greenstein, Chief Financial Officer. Before we begin, I would like to caution that comments made during this call will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements made on this call that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding the market in which Carls Med operates, trends, expectations, and demand for Carls Med's products, expectations with respect to reimbursement, statements about the company's clinical data, surgeon adoption, and utilization, and Carls Med's expected financial performance and position in the market. Any forward-looking statements made during this call, including projections for future performance, is based on management's expectations as of today. Carls Med undertakes no obligation to update these statements except as required by applicable law. These statements are neither promises nor guarantees and are subject to known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement. For more detailed information, please review the cautionary notes on the earnings materials accompanying today's presentation, as well as Carls Med's filings with the SEC. particularly the risk factors described in Carls Med's annual report on Form 10-K for the year ended December 31st to 2025. I encourage you to review all Carls Med's filings with the SEC concerning these and other matters. Additionally, during today's call, management will discuss certain non-GAAP financial measures, including adjusted EBITDA. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures is included in today's earnings press release. These filings along with Carls Med's press release for the first quarter of 2026 results are available on Carls Med's website at www.carlsmed.com under the investor section and include additional information about Carls Med's financial results. A recording of today's call will also be available on Carls Med's website by 5 p.m. Pacific time today. I would like to turn the call over to Mike to go over Carls Med's business highlights.